Decoding the Limits of Modern Therapeutics: New Stanford-Led Study Reveals Genetic Roots of "GLP-1 Resistance"
Executive Overview With over a quarter of all Type 2 diabetes patients globally relying on GLP-1 receptor agonists—a revolutionary class of medications that includes blockbuster treatments like Ozempic—a significant clinical…